SPATA13

Chr 13

spermatogenesis associated 13

Also known as: ARHGEF29, ASEF2

SPATA13 encodes a guanine nucleotide exchange factor that activates RHO family GTPases (RHOA, RAC1, CDC42) to regulate cell migration, adhesion, and plasma membrane projection assembly. Mutations cause autosomal recessive intellectual disability with macrocephaly and seizures, typically presenting in early childhood. The gene shows moderate constraint against loss-of-function variants (LOEUF 0.462), suggesting some intolerance to complete protein loss.

OMIMResearchSummary from RefSeq, UniProt
MultiplemechanismLOEUF 0.46
Clinical SummarySPATA13
🧬
Gene-Disease Validity (ClinGen)
primary angle-closure glaucoma · ADLimited

Limited evidence — not for standalone diagnostic reporting

Population Constraint (gnomAD)
Constrained for loss-of-function variants (OE-LoF 0.30) despite low pLI — interpret in context.
📋
ClinVar Variants
40 unique Pathogenic / Likely Pathogenic· 230 VUS of 337 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Moderate LoF intolerance
LoF Constraint
0.46LOEUF
pLI 0.003
Z-score 4.50
OE 0.30 (0.190.46)
Moderately constrained

More LoF-intolerant than ~75% of genes

Missense Constraint
2.03Z-score
OE missense 0.80 (0.750.85)
636 obs / 796.9 exp
Mild constraint

Moderately missense-constrained (top ~2.5%)

Observed / Expected Ratios
LoF OE0.30 (0.190.46)
00.351.4
Missense OE0.80 (0.750.85)
00.61.4
Synonymous OE0.88
01.21.6
LoF obs/exp: 14 / 47.4Missense obs/exp: 636 / 796.9Syn Z: 1.78
DN
0.77top 25%
GOF
0.72top 25%
LOF
0.3066th %ile

This gene has evidence for multiple mechanisms of pathogenicity (dominant-negative and gain-of-function). Both the Badonyi & Marsh prediction and the broader genomic evidence point to dominant-negative as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

DNprediction above median
GOFprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

337 submitted variants in ClinVar

Classification Summary

Pathogenic37
Likely Pathogenic3
VUS230
Likely Benign39
Benign9
Conflicting1
37
Pathogenic
3
Likely Pathogenic
230
VUS
39
Likely Benign
9
Benign
1
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
37
0
37
Likely Pathogenic
0
0
3
0
3
VUS
0
200
30
0
230
Likely Benign
0
17
12
10
39
Benign
0
5
3
1
9
Conflicting
1
Total02228511319

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

SPATA13 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

3D Protein StructureAlphaFold

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Open Research Assistant →